Cefoselis Side Chain Intermediate Manufacturer in India

Swapnroop Pharma · WHO-GMP Certified · +91 87670 62101

Cefoselis Side Chain Intermediate Manufacturer in India 

SDP presents 5-Formamido-1-[2-(formyloxy)ethyl]pyrazole as a specialized pharmaceutical intermediate used in the synthesis of Cefoselis. Also known as 2-(5-formamidopyrazol-1-yl)ethyl formate, this compound is a substituted pyrazole derivative containing formamido and formate ester functional groups.

This intermediate is associated with the synthesis of Cefoselis, a fourth-generation cephalosporin antibacterial agent. Its protected pyrazole structure is used during the preparation of the characteristic pyrazolium-containing side-chain portion of the Cefoselis molecule.

Product Name: 5-Formamido-1-[2-(formyloxy)ethyl]pyrazole
Common Name: Cefoselis Side Chain Intermediate
CAS Number: 116856-18-9
Molecular Formula: C₇H₉N₃O₃
Molecular Weight: 183.17 g/mol
Product Category: Pharmaceutical Intermediate
Application: Cefoselis synthesis

Chemical Information

ParameterDetails
Chemical name5-Formamido-1-[2-(formyloxy)ethyl]pyrazole
IUPAC name2-(5-formamidopyrazol-1-yl)ethyl formate
CAS number116856-18-9
Molecular formulaC₇H₉N₃O₃
Molecular weight183.17 g/mol
Molecular structureSubstituted pyrazole derivative
Functional groupsFormamido group and formate ester
Product typePharmaceutical intermediate
Related APICefoselis

Applications

Cefoselis Synthesis

5-Formamido-1-[2-(formyloxy)ethyl]pyrazole is identified as a side-chain intermediate in Cefoselis synthesis. It provides a protected pyrazole building block for the preparation of the pyrazole-containing portion of the antibiotic molecule.

Pharmaceutical Process Development

The compound may be used in process-development activities involving pyrazole derivatives and cephalosporin intermediates, subject to the requirements of the relevant synthesis route.

Research and Development

Potential applications include:

  • Pharmaceutical intermediate research
  • Cephalosporin process development
  • Heterocyclic compound synthesis
  • Analytical method development
  • Reference and process-control studies

Role in Cefoselis Manufacturing

Cefoselis is a cephalosporin antibacterial agent. The synthesis route described in patent-related literature uses a formyl-protected hydroxyethyl pyrazole intermediate in the preparation of the pyrazolium-containing cephem structure.

The formamido and formate ester groups are part of the protected intermediate structure. Subsequent synthesis steps transform the protected intermediate into the required substituted pyrazole portion of the Cefoselis molecule.

The exact reaction sequence, reagents, process conditions and impurity profile depend on the selected manufacturing route and validated process.

Physical and Chemical Properties

PropertyReported information
AppearanceWhite to almost white or pale-yellow crystalline powder; confirm batch appearance
Molecular formulaC₇H₉N₃O₃
Molecular weight183.17 g/mol
CAS number116856-18-9
Melting pointApproximately 84–88°C, depending on source and material
SolubilityConfirm using product-specific analytical data
Chemical natureFormamido-substituted pyrazole ester

Reported physical properties are reference information and should not be treated as approved batch-release limits without verification against the supplier's specification and Certificate of Analysis.

Quality and Analytical Documentation

Quality evaluation of 5-Formamido-1-[2-(formyloxy)ethyl]pyrazole may include:

  • Identity confirmation by appropriate spectroscopic or chromatographic methods
  • Assay or purity determination by a validated analytical method
  • Related-substances and impurity profiling
  • Residual solvent testing, where applicable
  • Water content determination, where required
  • Physical appearance and melting-range evaluation

Analytical methods and acceptance criteria should be established and approved for the intended manufacturing process. HPLC or GC purity values reported by research-chemical vendors are not automatically applicable as commercial manufacturing specifications.

Batch-specific documentation should be reviewed before material approval.

Packaging and Storage

Packaging should protect the material from contamination, moisture and unsuitable environmental exposure.

Recommended handling principles:

  • Use clean, dry and chemically compatible packaging.
  • Keep containers tightly closed when not in use.
  • Protect the material from excessive moisture and unsuitable storage conditions.
  • Follow the approved product specification and stability data for the storage temperature.
  • Use suitable secondary packaging for transport.

The final packaging configuration and storage conditions should be confirmed from validated stability information and the batch documentation.

Safety and Handling

This compound is a chemical intermediate intended for controlled industrial, laboratory or pharmaceutical manufacturing use. It is not a finished medicine.

Recommended precautions:

  • Handle in a suitable, ventilated work area.
  • Avoid unnecessary dust generation and inhalation.
  • Avoid contact with skin and eyes.
  • Use appropriate gloves, protective clothing and eye protection.
  • Follow the current Safety Data Sheet (SDS).
  • Dispose of material and packaging according to applicable regulations.

No patient-use or dosage information applies to this raw material.

Frequently Asked Questions

1. What is 5-Formamido-1-[2-(formyloxy)ethyl]pyrazole?
It is a substituted pyrazole pharmaceutical intermediate used as a side-chain building block in Cefoselis synthesis.

2. What is the CAS number?
The CAS number is 116856-18-9.

3. What is its molecular formula?
Its molecular formula is C₇H₉N₃O₃.

4. What is its molecular weight?
Its molecular weight is approximately 183.17 g/mol.

5. Is this product a Cefoselis API?
No. It is a pharmaceutical intermediate used in Cefoselis synthesis, not the finished Cefoselis API.

6. What is its reported melting point?
Published supplier references report a melting range around 84–88°C. The actual acceptance range should be confirmed against the approved product specification.

7. Is the product suitable for pharmaceutical manufacturing?
Suitability depends on the customer's process requirements, approved specification, analytical results and quality documentation.

8. Which analytical documents should be requested?
A batch-specific Certificate of Analysis and Safety Data Sheet should be requested. Additional analytical and quality documents may be required by the customer's qualification procedure.

Enquiry for Cefoselis Side Chain Intermediate

For product information, specifications, analytical documentation, packaging details and commercial enquiries regarding 5-Formamido-1-[2-(formyloxy)ethyl]pyrazole, contact SDP.

SDP – Pharmaceutical Intermediates and Specialty Chemicals

Please share your required quantity, target specification, intended application and documentation requirements to support your enquiry.

Detailed Specifications

Parameter Specification
Appearance White to almost white
Identification IR and HPLC complaint
Assay (HPLC) 98.5–101.0%
Loss on Drying NMT 6.0%
Residue on Ignition NMT 0.2%
Heavy Metals NMT 10 ppm
Solubility Slightly soluble in water
Get Bulk Quote via WhatsApp
chatbot/chatbot.js" defer>